Results 21 to 30 of about 5,328 (181)

Evolution of acquired resistance in a ROS1+ KRAS G12C+ NSCLC through the MAPK pathway

npj Precision Oncology, 2023
Patients with metastatic NSCLC bearing a ROS1 gene fusion usually experience prolonged disease control with ROS1-targeting tyrosine kinase inhibitors (TKI), but significant clinical heterogeneity exists in part due to the presence of co-occurring genomic
Katherine Priest, Anh Le, Amanuail Gebregzabheir, Hala Nijmeh, Gregory B. Reis, Melanie Mandell, Kurtis D. Davies, Carolyn Lawrence, Emily O’Donnell, Robert C. Doebele, Liming Bao, Dara L. Aisner, Erin L. Schenk   +12 more
doaj   +1 more source

Comparative effectiveness of larotrectinib and entrectinib for TRK fusion cancer. [PDF]

, 2022
Larotrectinib and entrectinib are tumor-agnostic tropomyosin receptor kinase (TRK) inhibitors that are indicated for the treatment of advanced or metastatic solid tumor cancers with neurotrophic tyrosine receptor kinase (NTRK) gene fusions.
Brose, Marcia S, Carlson, Josh J, Federman, Noah, Italiano, Antoine, Kummar, Shivaani, Lassen, Ulrik, Sullivan, Sean D   +6 more
core   +1 more source

Entrectinib‐induced syndrome of inappropriate antidiuretic hormone secretion in a patient with ROS1‐rearranged non‐small cell lung cancer

Respirology Case Reports, 2023
A 75‐year‐old woman was referred to our hospital because of a productive cough and an abnormal shadow on chest radiography. She was diagnosed as having metastatic lung adenocarcinoma harbouring ROS proto‐oncogene 1 (ROS1).
Chiaki Kato, Muneyuki Sekiya, Ryo Sekiguchi, Akira Yamasaki, Takahiro Yoshizawa, Kazutoshi Isobe, Naobumi Tochigi, Kazutoshi Shibuya, Kazuma Kishi   +8 more
doaj   +1 more source

Patient-reported outcomes from STARTRK-2: a global phase II basket study of entrectinib for ROS1 fusion-positive non-small-cell lung cancer and NTRK fusion-positive solid tumours. [PDF]

, 2021
Patient-reported outcomes (PROs) are increasingly relevant endpoints in clinical trials, contributing to our understanding of risk-benefit profiles, in addition to efficacy and safety data.
Ahn, M-J, Barlesi, F, Chen, D, Conley, A, Demetri, G, Doebele, R, Drilon, A, Kapre, A, McCallum, S, Osborne, S, Paz Ares, Luis Gonzaga, Rolfo, C, Seto, T, Siena, S, Wolf, J   +14 more
core   +2 more sources

Therapeutical Options in ROS1—Rearranged Advanced Non Small Cell Lung Cancer [PDF]

, 2023
ROS proto-oncogene 1 (ROS1) rearrangements occur in 0.9–2.6% of patients with non small cell lung cancer (NSCLC), conferring sensitivity to treatment with specific tyrosine-kinase inhibitors (TKI). Crizotinib, a first-generation TKI, was the first target-
Bearz A., Bertoli E., De Carlo E., Del Conte A., Revelant A., Spina M., Stanzione B.   +6 more
core   +1 more source

Development and Validation of an Ecofriendly, Rapid, Simple and Sensitive UPLC-MS/MS Method for Entrectinib Quantification in Plasma for Therapeutic Drug Monitoring

Separations, 2023
Entrectinib is an oral selective inhibitor of the neurotrophic T receptor kinase (NTRK). It is used in the treatment of solid tumors in NTRK gene fusion lung cancer. The study aimed to develop and validate an analytical method for quantifying entrectinib
Essam A. Ali, Muzaffar Iqbal, Gamal A. E. Mostafa, Rashad Al Salahi   +3 more
doaj   +1 more source

Case report: EML4::NTRK3 gene fusion in a patient with metastatic lung adenocarcinoma successfully treated with entrectinib

Frontiers in Oncology, 2022
Rearrangements involving the neurotrophin kinase (NTRK) genes NTRK1, NTRK2 and NTRK3 with different fusion partners have been observed in both adult and pediatric solid tumors.
Chiara Lazzari, Lorenza Pecciarini, Claudio Doglioni, Federica Pedica, Ana Maria Samanes Gajate, Alessandra Bulotta, Vanesa Gregorc, Maria Giulia Cangi   +7 more
doaj   +1 more source

Entrectinib—A SARS-CoV-2 Inhibitor in Human Lung Tissue (HLT) Cells [PDF]

, 2021
COVID-19; Drug repurposing; Viral cell entry assaysCOVID-19; Reutilización de medicamentos; Ensayos de entrada de células viralesCOVID-19; Reutilització de medicaments; Assajos d'entrada de cèl·lules viralsSince the start of the COVID-19 outbreak ...
Ayinampudi, Vikram, Buzón Gómez, María José, Genesca Ferrer, Meritxell, Grau Exposito, Judit, Peralta-Garcia, Alejandro, Perea Pérez, David, Stepniewski, Tomasz Maciej, Torrens-Fontanals, Mariona   +7 more
core   +1 more source

Inhibition of MEK1/2 Forestalls the Onset of Acquired Resistance to Entrectinib in Multiple Models of NTRK1-Driven Cancer

Cell Reports, 2020
Summary: NTRK1 gene fusions are actionable drivers of numerous human malignancies. Here, we show that expression of the TPR-NTRK1 fusion kinase in immortalized mouse pancreatic ductal epithelial (IMPE) (pancreas) or mouse lung epithelial (MLE-12) cells ...
Aria Vaishnavi, Michael T. Scherzer, Conan G. Kinsey, Gennie L. Parkman, Amanda Truong, Phaedra Ghazi, Sophia Schuman, Benjamin Battistone, Ignacio Garrido-Laguna, Martin McMahon   +9 more
doaj   +1 more source

Potential novel therapy targets in neuroendocrine carcinomas of the breast [PDF]

, 2018
Neuroendocrine carcinoma (NEC) of the breast is a rare, special type of breast cancer, reportedly constituting 2% to 5% of all breast cancers. Although breast NEC does not have a specific targeted therapy, several new targeted therapies based on specific
Contreras, Elma, Florento, Elena, Gatalica, Zoran, Palazzo, Juan, Sanati, Souzan, Swensen, Jeffrey, Vranic, Semir, Xiu, Joanne   +7 more
core   +2 more sources